Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

por Melisi, Davide, Garcia-Carbonero, Rocio, Macarulla, Teresa, Pezet, Denis, Deplanque, Gael, Fuchs, Martin, Trojan, Jorg, Oettle, Helmut, Kozloff, Mark, Cleverly, Ann, Smith, Claire, Estrem, Shawn T., Gueorguieva, Ivelina, Lahn, Michael M. F., Blunt, Al, Benhadji, Karim A., Tabernero, Josep
Publicado 2018